Previous studies have shown that improving vitamin D status among the elderly may lead to an improvement in some inflammatory markers, especially with patients with type 2 diabetes. The aim of our trial is study the effect of vitamin D supplementation on inflammatory markers in patients having type 2 diabetes.
Vitamin D was shown crucial for insulin secretion and glucose homeostasis. Furthermore, one of the markers of type 2 diabetes is low-grade inflammation, which can be the result of an elevated circulation of cytokines. High amounts of circulating inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contribute significantly to insulin resistance in muscle and adipose tissues. The aim of this randomized, controlled, double blind study is to examine the effect of vitamin D supplementation on some inflammatory markers in older Lebanese patients having type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
88
The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
Saint Charles Hospital
Beirut, Lebanon
Change from Baseline fasting blood glucose (FBG) at 6 months
FASTING BLOOD GLUCOSE
Time frame: baseline and after 6 months of intervention
Change from Baseline Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6 months
Homeostatic Model Assessment of Insulin Resistance
Time frame: baseline and after 6 months of intervention
Change from Baseline C-reactive protein (CRP) at 6 months
C-reactive protein
Time frame: baseline and after 6 months of intervention
Change from Baseline Interleukin-6 (IL-6) at 6 months
Interleukin-6
Time frame: baseline and after 6 months of intervention
Change from Baseline TNF-alpha at 6 months
TNF-alpha
Time frame: baseline and after 6 months of intervention
Change from Baseline weight at 6 months
weight change
Time frame: baseline and after 6 months of intervention
Change from Baseline Body Mass Index (BMI) at 6 months
Body mass index
Time frame: baseline and after 6 months of intervention
Change from Baseline waist circumference at 6 months
Waist circumference change
Time frame: baseline and after 6 months of intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from Baseline Percentage of fat at 6 months
Percentage of fat
Time frame: baseline and after 6 months of intervention
Change from Baseline Parathyroid hormone (PTH) at 6 months
Parathyroid hormone
Time frame: baseline and after 6 months of intervention